All Releases
 |
MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results
Mar 2, 2010
|
15.5 KB |
|
| |
MOUNTAIN VIEW, Calif., March 2, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2009.
The net loss for the fourth quarter ended December 31, 2009 was $13.4 million compared to $21.8 million during the same period in 2008. The ...
|
|
MAP Pharmaceuticals to Present at Upcoming Healthcare Conferences
Feb 23, 2010
|
7.0 KB |
|
| |
MOUNTAIN VIEW, Calif., Feb 23, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following events in March:
RBC Capital Markets 2010 Healthcare Conference
Panel: Specialty Pharma - Adapting a Changing Business Model
Tuesday, March 2, a...
|
|
MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial
Feb 16, 2010
|
10.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Feb 16, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company initiated a trial to compare the pharmacokinetics (PK), safety and metabolic profiles of LEVADEX(TM) orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and n...
|
|
MAP Pharmaceuticals Announces FDA will not Require a Second Pivotal Efficacy Study for LEVADEX(TM) NDA Submission
Jan 11, 2010
|
11.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan 11, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatme...
|
|
MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
Jan 6, 2010
|
6.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan 06, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the 28th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2010 at 9:00 a.m. PT in San Francisco.
A live webcast of the presentation will be available on the Investor...
|
|
MAP Pharmaceuticals Appoints Alan Petro Vice President, Manufacturing and Technical Operations
Dec 1, 2009
|
10.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Dec 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Alan Petro to the newly created position of Vice President, Manufacturing and Technical Operations. In his new role, Mr. Petro will lead the company's efforts in the area of product/proces...
|
|
MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility
Nov 12, 2009
|
10.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has secured a committed equity financing facility under which it may sell up to $60 million of its registered common stock to Azimuth Opportunity Ltd. MAP Pharmaceuticals is not obligated to utilize...
|
|
MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
Nov 11, 2009
|
6.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, 2009 at 9:00 a.m. ET in New York City.
A live webcast of the presentation will be avai...
|
|
MAP Pharmaceuticals Reports Third Quarter of 2009 Financial Results
Nov 5, 2009
|
14.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the third quarter ended September 30, 2009.
Net income for the quarter ended September 30, 2009 was $19.3 million, compared to a net loss of $20.4 million during the same period in 200...
|
|
MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients
Oct 29, 2009
|
10.4 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's Phase 3 FREEDOM 301 clinical trial with its LEVADEX(TM) orally inhaled migraine therapy.
...
|
|
'Headache' Publication Describes Potential Mechanistic Rationale for LEVADEX(TM) Favorable Adverse Event Profile
Sep 22, 2009
|
10.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Sept 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced publication of results from an in vitro study of its novel LEVADEX(TM) (MAP0004) orally inhaled migraine therapy in development exploring the potential mechanism by which the pharmacokinetics (PK) and pharm...
|
|
MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Sep 10, 2009
|
14.2 KB |
|
| |
MOUNTAIN VIEW, Calif., Sept 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that it will present analysis of data from the efficacy portion of the first Phase 3 trial of its novel LEVADEX(TM) orally inhaled migraine therapy, currently in development, at the 14th Congress of the Int...
|
|
MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
Sep 2, 2009
|
7.0 KB |
|
| |
MOUNTAIN VIEW, Calif., Sept 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it will participate in the following events in September:
Thomas Weisel Partners Healthcare Conference 2009
Friday, September 11, at 10:20 a.m. ET in Boston
14th Congress of the Inte...
|
|
MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
Aug 6, 2009
|
8.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Aug 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today the pricing of its previously announced public offering of 3,500,000 shares of its common stock at a public offering price of $9.70 per share. Net proceeds, after estimated underwriting discounts and commiss...
|
|
MAP Pharmaceuticals, Inc. Announces Public Offering of Common Stock
Aug 5, 2009
|
7.5 KB |
|
| |
MOUNTAIN VIEW, Calif., Aug 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today its intention, subject to market and other conditions, to offer 3,500,000 shares of its common stock in a registered public offering pursuant to its existing shelf registration statement. MAP Pharmaceuticals...
|
|
MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
Aug 3, 2009
|
13.7 KB |
|
| |
MOUNTAIN VIEW, Calif., Aug 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the second quarter ended June 30, 2009.
The net loss for the quarter ended June 30, 2009 was $5.0 million, compared to $16.5 million during the same period in 2008. The net loss for th...
|
|
MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration
Jul 9, 2009
|
8.4 KB |
|
| |
MOUNTAIN VIEW, Calif., July 9, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has received a notice of termination of the license agreement with AstraZeneca related to the company's Unit Dose Budesonide (UDB) product candidate. The termination was received on July 8, 2009, ef...
|
|
MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
May 26, 2009
|
14.5 KB |
|
| |
MOUNTAIN VIEW, Calif., May 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX(TM) orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provid...
|
|
MAP Pharmaceuticals Announces Presentations at the American Thoracic Society International Conference
May 14, 2009
|
7.4 KB |
|
| |
MOUNTAIN VIEW, Calif., May 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it will present three posters on its Unit Dose Budesonide (UDB) pediatric asthma therapy clinical program and one poster on its MAP0005 formoterol-budesonide combination asthma therapy program at ATS 20...
|
|
MAP Pharmaceuticals to Present at the Deutsche Bank Securities 34th Annual Health Care Conference
May 13, 2009
|
6.9 KB |
|
| |
MOUNTAIN VIEW, Calif., May 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the Deutsche Bank Securities 34th Annual Health Care Conference on Tuesday, May 19, 2009 at 2:35 p.m. (ET) in Boston, MA.
A live webcast of the presentation will be availabl...
|
|
|
